Physician

Jonathan Andrew Kendall, MD

According to 2025 Medicare claims, Jonathan Kendall, MD (NPI: 1548424773) practices nephrology in the Huntington-Ashland, WV-KY-OH market, with the plurality of this provider's patient population coming from Greenup, KY. This provider's primary affiliated billing organization is KINGS DAUGHTERS MEDICAL SPECIALTIES INC (NPI: 1184912453; TIN: 264183569) and primary practice location at 41101-2843.

Kendall's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 438 traditional Medicare patients, billed 1,236 HCPCS/CPT codes, and received $125,613 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,866 prescription claims across 378 beneficiaries totaling $598,730 in drug costs, led by Velphoro (Sucroferric Oxyhydroxide). 2017 DME data shows 108 claims. Open Payments data shows 28 records totaling $609. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $282,278 to $125,613. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $395,211 and ending at $598,730. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,129	3,587	$282,278
2016	1,144	3,800	$315,266
2017	1,083	3,616	$301,651
2018	1,018	3,521	$282,841
2019	1,016	3,480	$296,224
2020	728	2,861	$237,141
2021	679	2,321	$218,983
2022	541	1,716	$172,315
2023	482	1,429	$150,824
2024	438	1,236	$125,613

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	357	2,323	$395,211
2016	376	2,504	$464,793
2017	376	2,695	$654,370
2018	390	2,318	$394,719
2019	353	2,052	$610,820
2020	358	2,100	$974,429
2021	367	2,000	$703,388
2022	357	1,753	$752,008
2023	388	2,058	$819,583
2024	378	1,866	$598,730

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$493
2016	N/R	N/R	N/R
2017	N/R	108	$48,831
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	45	47	$125
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	43	47	$95
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	44	88	$88
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	160	218	$61
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	183	494	$58

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Velphoro	Sucroferric Oxyhydroxide	35	1,350	$155,482
Auryxia	Ferric Citrate	46	1,860	$84,228
Farxiga	Dapagliflozin Propanediol	88	4,295	$78,026
Tolvaptan	Tolvaptan	21	850	$44,345
Jardiance	Empagliflozin	52	2,040	$38,778

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	28	$609	Otsuka America Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Jonathan Andrew Kendall, MD?

Tedicare shows public-source Medicare data for Jonathan Andrew Kendall, MD (NPI 1548424773), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Jonathan Andrew Kendall, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Jonathan Andrew Kendall, MD?

Jonathan Andrew Kendall, MD is linked to KINGS DAUGHTERS MEDICAL SPECIALTIES INC (billing NPI 1184912453) in the available physician profile data.

Does Jonathan Andrew Kendall, MD have Open Payments data?

Jonathan Andrew Kendall, MD has 28 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.